Skip to main content
Home Home

User account menu

Log in

Main navigation

  • Home
  • Topics
    • Biological medicines
    • Cardiovascular disease
    • Equity
    • Focus medicines
    • Gout
    • Type 2 diabetes
  • Resources
    • All education/search
    • Events
    • HAH Bulletins
    • Podcasts
    • Recorded webinars
    • Reflection activities
    • Resource hubs
    • Videos
  • EPiC dashboard
    • Go to EPiC
    • Join EPiC
    • EPiC FAQ
    • EPiC Demo
    • About EPiC
    • Win with EPiC!
  • News
    • That's Interesting
    • From The Team

Education

  1. Home
  2. Search

The hub for all your learning resources.

Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.

The patient voice: Moving to Amgevita

3 minutes to Watch

This short video explores what patients think about the move to Amgevita. We spoke to a group of seven New Zealanders living with arthritis to find out how they feel about changing from the biological reference medicine, Humira, to the new biosimilar medicine, Amgevita. 

Contributor
He Ako Hiringa
14 April 2022
  • Biological medicines
  • Videos
Covid image

Treating COVID-19 with Paxlovid in primary care

8 minutes to Read + 7 minutes to Delve

Since 1 April 2022, the oral antiviral combination nirmatrelvir/ritonavir (Paxlovid) has been listed on the Pharmaceutical Schedule for treating patients with COVID-19 in the community. This resource for prescribers and dispensing pharmacists links to Pharmac's access criteria and to comprehensive drug interaction guidance.

Contributor
Eamon Duffy
31 March 2022
  • COVID-19
  • Reflection activities
Bulletin 12

Is your CVD management aggressive enough?

1 minute to Read

The current primary care CVD management guidance strongly recommends aggressive risk management and lifestyle modification in patients with pre-existing CVD or an equivalent CVD risk. Significant opportunities to improve use of CVD medicines remain, particularly for Māori and Pacific peoples who lose 2.6–2.8 times more years to CVD events relative to non-Māori/non-Pacific peoples.

Contributor
He Ako Hiringa
30 March 2022
  • HAH Bulletins
  • CVD
Laptop open and leaning against a pile of books

Resource hubs

Looking for up-to-date information on gout or biological medicines? You can find it in our resource hubs. We’ve linked resources from multiple providers into one place so it’s easy for you to find what you need - articles, datasheets, videos, podcasts, and more.

29 March 2022
  • Gout
  • Biological medicines
Hand holding a magnifying glass over the word focus

Focus medicines index

Explore our range of resources, listed by the name of the medicine on which they focus.

28 March 2022

Humira to Amgevita - Experience from over the ditch

90 minutes to Watch

This recorded webinar covers the introduction of the adalimumab biosimilar Amgevita in New Zealand, and what it means for primary care. Specialist Dr David Liew shares his experiences of changing patients from biologics to biosimilars in Australia, and Andrea Copeland provides some local context.

Contributor
Dr David Liew, Andrea Copeland
17 March 2022
  • Recorded webinar
  • Biological medicines
Pondering the complexities of preventing cardiovascular disease

Pondering the complexities of preventing cardiovascular disease

6 minutes to Read + 9 minutes to Delve

In this article, Dr Jim Vause contemplates managing CVD risk, reasons for non-adherence, inequities in CVD treatment, and how to improve communication with patients. 

Contributor
Dr Jim Vause
10 March 2022
  • CVD
Bulletin 11

Adalimumab biosimilar improves access

1 minute to Read

Adalimumab is used to treat a range of dermatological, rheumatological, gastrointestinal and ophthalmologic conditions. From 1 March, Amgevita (an adalimumab biosimilar) is funded under Special Authority. From this date, patients starting treatment with adalimumab will receive Amgevita rather than the reference product, Humira. 

Contributor
He Ako Hiringa
1 March 2022
  • HAH Bulletins
  • Biological medicines

Achieving equity in gout management

90 minutes to Watch

In this recorded webinar, Professor Lisa Stamp explores the management of gout as a long-term condition and challenges old beliefs. Dr Noni Richards introduces the EPiC Gout dashboard and outlines how it can be used to highlight and address inequities. 

Contributor
Professor Lisa Stamp, Dr Noni Richards
25 February 2022
  • Recorded webinar
  • Gout
Biological medicines hub

Biological medicines resource hub

Looking for up-to-date information on biological medicines? You can find it here!

We’ve linked resources from multiple providers into one place so it’s easy for you to find what you need.

 

Contributor
He Ako Hiringa
14 February 2022
  • Biological medicines
Transition to adalimumab biosimilar

Transition to adalimumab biosimilar

13 minutes to Read + 47 minutes to Delve

This article summarises the 2022 changes regarding adalimumab funding and access in New Zealand. It also provides some background and resources to foster confidence in biosimilars, and references real-world data from studies of patients changing from Humira to Amgevita.

Contributor
He Ako Hiringa
14 February 2022
  • Biological medicines
Bulletin 10

Cardiovascular disease - a risky business

1 minute to Read

Cardiovascular disease is the leading cause of death in New Zealand, accounting for 35 per cent of mortality in 2019. Yet it’s preventable and treatable. Māori, Pacific, and South Asian peoples have a disproportionately higher CVD risk compared with people not of these ethnicities. Therefore, CVD risk assessments in these ethnicities should begin earlier.

Contributor
He Ako Hiringa
28 January 2022
  • HAH Bulletins
  • CVD

Pagination

  • « First First page
  • ‹ Previous Previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next › Next page
  • Last » Last page
Home Home

Contact Us

11 Omana Road, Milford Auckland NZ, 0620

PO Box 31905, Milford Auckland NZ, 0741

Support

09 488 4286

admin@akohiringa.co.nz

(9-5pm Mon-Fri)

Contact us

About us

Terms & Policies

  • Conditions for Use
  • Privacy Policy

Supported by

Pharmac

© Matui Limited. All rights reserved.

Developed by Matui Limited and brought to life by Communica.